Organization
University Hospital rechts der Isar
1 abstract
Abstract
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.Org: Schleswig-Holstein University Hospital, Hospital Salzburg Paracelus University, University Hospital rechts der Isar, Jena University Hospital, Wuerzburg University Medical Center,